



#123
Dec
7/10/03

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:

July 3, 2003
Date

Gina N. Shishima

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Chada et al.

Serial No.: 10/017,472

Filed: December 7, 2001

For: METHODS OF TREATMENT
INVOLVING HUMAN MDA-7

Group Art Unit: 1632

Examiner: Li, Qian J.

Atty. Dkt. No.: INGN:097US

RECEIVED
JUL 09 2003
TECH CENTER 1600/2900

I. AMENDMENT; AND II. RESPONSE TO RESTRICTION REQUIREMENT
DATED JUNE 3, 2003

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Office Communication dated June 3, 2003 ("Office Communication"), for which the date for response is July 3, 2003.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/INGN:097US.

07/10/2003 DJACUBS 00000002 501212 10017472

I. AMENDMENT 01 FC:2201 42.00 DA

Please cancel claims 26-31, without prejudice or disclaimer.

Please amend the following claim:

6.

B1

(Amended once) The method of claim 3, wherein the ocular angiogenic disease is further defined as diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, or Rubeosis.

Please add the following claims:

--68. The method of claim 32, wherein the MDA polypeptide comprises amino acids from 175 to 206 of SEQ ID NO:2.

69. The method of claim 68, wherein the MDA polypeptide comprises amino acids from 150 to 206 of SEQ ID NO:2.

70. The method of claim 69, wherein the MDA polypeptide comprises amino acids from 125 to 206 of SEQ ID NO:2.

B2

71. The method of claim 70, wherein the MDA polypeptide comprises amino acids from about 100 to about 206 of SEQ ID NO:2.

72. The method of claim 71, wherein the MDA polypeptide comprises amino acids from 75 to 206 of SEQ ID NO:1.

73. The method of claim 72, wherein the MDA polypeptide comprises amino acids from 49 to 206 of SEQ ID NO:2.

74. The method of claim 73, wherein the MDA polypeptide comprises amino acids from 1 to 206 of SEQ ID NO:2.--